Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 ?g per million cells in 100 ?L?volume. It is recommended that the reagent be titrated for optimal performance for each application.

Additional reported applications (for the relevant formats) include: immunofluorescence⁴, blocking^6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections^{4, 11}. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

1. Maier H, et al. 2007. J. Immunol. 178:2714.
2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed

1. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
2. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
3. Dieterich LC, et al. 2017. Front Immunol. 0.379166667. PubMed
4. Iwai T, et al. 2021. Mol Cancer Ther. 20:2519. PubMed
5. Muhammad F, et al. 2020. Front Immunol. 975:11. PubMed
6. Herold M, et al. 2015. J Immunol. 195: 3584 - 3595. PubMed
7. Wang G, et al. 2020. Nat Commun. 11:1395. PubMed
8. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
9. Tan Z, et al. 2020. Mol Ther Oncolytics. 16:302. PubMed
10. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
11. Lei G, et al. 2015. Infect Immun . 83:572. PubMed
12. Singh M, et al. 2017. Nat Commun. 8:1447. PubMed
13. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
14. Meng Q, et al. 2006. Invest Ophthalmol Vis Sci. 47:4444. PubMed
15. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
16. Kong F, et al. 2021. Front Immunol. 12:670646. PubMed
17. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
18. Yahata T, et al. 2019. Cancer Sci. 110:1279. PubMed
19. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
20. Speranza MC, et al. 2018. Neuro Oncol. 20:225. PubMed
21. Sano Y, et al. 2021. Mol Cancer Res. 19:507. PubMed
22. Zhao T, et al. 2022. JCI Insight. 7:. PubMed
23. Scarlett U, et al. 2012. J Exp Med. 209:425. PubMed
24. Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed
25. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
26. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
27. Lin A, et al. 2022. Bioeng Transl Med. 7:e10314. PubMed
28. Iida Y, et al. 2020. J Immunother Cancer. 8:. PubMed
29. Bassi &, et al. 2012. Diabetes. 61:2534. PubMed
30. Li Z, et al. 2022. Transl Cancer Res. 11:3698. PubMed
31. Hirose T, et al. 2017. PLoS One. 12(6):e0178765. PubMed
32. Knier B, et al. 2018. Nat Immunol. 1.722916667. PubMed
33. Giles DA, et al. 2018. J Clin Invest. 128:5322. PubMed
34. Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.